Patients treated with high-dose intravenous immunoglobulin show selective activation of regulatory T cells

Clinical and Experimental Immunology

Volumn 173, Issue 2, 2013, Pages 259-267

  Tjon, A S W ^a   Tha In, T ^a   Metselaar, H J ^a   van Gent, R ^a   van der Laan, L J W ^a   Groothuismink, Z M A ^a   te Boekhorst, P A W ^a   van Hagen, P M ^a   Kwekkeboom, J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

human studies; intravenous immunoglobulin; IVIg; regulatory T cells

Indexed keywords

CD4 ANTIGEN; GAMMA INTERFERON; HLA DR ANTIGEN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; INTERLEUKIN 2 RECEPTOR ALPHA; NANOGAM; PREDNISONE; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL ARTICLE; COMMON VARIABLE IMMUNODEFICIENCY; CYTOKINE PRODUCTION; DERMATOMYOSITIS; DRUG MEGADOSE; EX VIVO STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE DEFICIENCY; IMMUNOGLOBULIN DEFICIENCY; LOW DRUG DOSE; LYMPHOCYTE DIFFERENTIATION; POLYCHONDRITIS; POLYMYOSITIS; POLYSEROSITIS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SYSTEMIC VASCULITIS; T LYMPHOCYTE ACTIVATION; VON WILLEBRAND DISEASE;

HUMAN STUDIES; INTRAVENOUS IMMUNOGLOBULIN; IVIG; REGULATORY T CELLS;

ADULT; AGED; ANTIGENS, CD4; AUTOIMMUNE DISEASES; CLINICAL PROTOCOLS; DRUG DOSAGE CALCULATIONS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HLA-DR ANTIGENS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC DEFICIENCY SYNDROMES; IMMUNOSUPPRESSION; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; T-LYMPHOCYTES, HELPER-INDUCER; T-LYMPHOCYTES, REGULATORY; YOUNG ADULT;

EID: 84880016002     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12102     Document Type: Article

References (35)

1. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001; 345:747-755.
2. Negi VS, Elluru S, Siberil S etal. Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol 2007; 27:233-245.
3. Kwekkeboom J, Tha-In T, Tra WM etal. Hepatitis B immunoglobulins inhibit dendritic cells and T cells and protect against acute rejection after liver transplantation. Am J Transplant 2005; 5:2393-2402.
4. Bucuvalas JC, Anand R, Studies of Pediatric Liver Transplantation Research G. Treatment with immunoglobulin improves outcome for pediatric liver transplant recipients. Liver Transpl 2009; 15:1564-1569.
5. Casadei DH, del C Rial M, Opelz G etal. A randomized and prospective study comparing treatment with high-dose intravenous immunoglobulin with monoclonal antibodies for rescue of kidney grafts with steroid-resistant rejection. Transplantation 2001; 71:53-58.
6. Sokos DR, Berger M, Lazarus HM. Intravenous immunoglobulin: appropriate indications and uses in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2002; 8:117-130.
7. Nimmerjahn F, Ravetch JV. Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol 2008; 26:513-533.
8. Tha-In T, Bayry J, Metselaar HJ, Kaveri SV, Kwekkeboom J. Modulation of the cellular immune system by intravenous immunoglobulin. Trends Immunol 2008; 29:608-615.
9. Kwekkeboom J. Modulation of dendritic cells and regulatory T cells by naturally occurring antibodies. Adv Exp Med Biol 2012; 750:133-144.
10. Sakaguchi S, Sakaguchi N, Shimizu J etal. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 2001; 182:18-32.
11. Tha-In T, Metselaar HJ, Bushell AR, Kwekkeboom J, Wood KJ. Intravenous immunoglobulins promote skin allograft acceptance by triggering functional activation of CD4+Foxp3+ T cells. Transplantation 2010; 89:1446-1455.
12. Ephrem A, Chamat S, Miquel C etal. Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. Blood 2008; 111:715-722.
13. Ramakrishna C, Newo AN, Shen YW, Cantin E. Passively administered pooled human immunoglobulins exert IL-10 dependent anti-inflammatory effects that protect against fatal HSV encephalitis. PLoS Pathog 2011; 7:e1002071.
14. Kessel A, Ammuri H, Peri R etal. Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function. J Immunol 2007; 179:5571-5575.
15. Wan YY, Flavell RA. Regulatory T-cell functions are subverted and converted owing to attenuated Foxp3 expression. Nature 2007; 445:766-770.
16. Itose I, Kanto T, Kakita N etal. Enhanced ability of regulatory T cells in chronic hepatitis C patients with persistently normal alanine aminotransferase levels than those with active hepatitis. J Viral Hepat 2009; 16:844-852.
17. McMurchy AN, Levings MK. Suppression assays with human T regulatory cells: a technical guide. Eur J Immunol 2012; 42:27-34.
18. Chi LJ, Wang HB, Zhang Y, Wang WZ. Abnormality of circulating CD4(+)CD25(+) regulatory T cell in patients with Guillain-Barre syndrome. J Neuroimmunol 2007; 192:206-214.
19. Furuno K, Yuge T, Kusuhara K etal. CD25+CD4+ regulatory T cells in patients with Kawasaki disease. J Pediatr 2004; 145:385-390.
20. Olivito B, Taddio A, Simonini G etal. Defective FOXP3 expression in patients with acute Kawasaki disease and restoration by intravenous immunoglobulin therapy. Clin Exp Rheumatol 2010; 28 (1 Suppl. 57):93-97.
21. Bayry J, Mouthon L, Kaveri SV. Intravenous immunoglobulin expands regulatory T cells in autoimmune rheumatic disease. J Rheumatol 2012; 39:450-451.
22. Costantino CM, Baecher-Allan C, Hafler DA. Multiple sclerosis and regulatory T cells. J Clin Immunol 2008; 28:697-706.
23. Lan RY, Ansari AA, Lian ZX, Gershwin ME. Regulatory T cells: development, function and role in autoimmunity. Autoimmun Rev 2005; 4:351-363.
24. Miyara M, Gorochov G, Ehrenstein M, Musset L, Sakaguchi S, Amoura Z. Human FoxP3+ regulatory T cells in systemic autoimmune diseases. Autoimmun Rev 2011; 10:744-755.
25. Segundo DS, Ruiz JC, Izquierdo M etal. Calcineurin inhibitors, but not rapamycin, reduce percentages of CD4+CD25+FOXP3+ regulatory T cells in renal transplant recipients. Transplantation 2006; 82:550-557.
26. Demirkiran A, Hendrikx TK, Baan CC, van der Laan LJ. Impact of immunosuppressive drugs on CD4+CD25+FOXP3+ regulatory T cells: does in vitro evidence translate to the clinical setting? Transplantation 2008; 85:783-789.
27. Demirkiran A, Sewgobind VD, van der Weijde J etal. Conversion from calcineurin inhibitor to mycophenolate mofetil-based immunosuppression changes the frequency and phenotype of CD4+FOXP3+ regulatory T cells. Transplantation 2009; 87:1062-1068.
28. Baan CC, van der Mast BJ, Klepper M etal. Differential effect of calcineurin inhibitors, anti-CD25 antibodies and rapamycin on the induction of FOXP3 in human T cells. Transplantation 2005; 80:110-117.
29. Coenen JJ, Koenen HJ, van Rijssen E, Hilbrands LB, Joosten I. Rapamycin, and not cyclosporin A, preserves the highly suppressive CD27+ subset of human CD4+CD25+ regulatory T cells. Blood 2006; 107:1018-1023.
30. Zeiser R, Nguyen VH, Beilhack A etal. Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood 2006; 108:390-399.
31. Gao W, Lu Y, El Essawy B, Oukka M, Kuchroo VK, Strom TB. Contrasting effects of cyclosporine and rapamycin in de novo generation of alloantigen-specific regulatory T cells. Am J Transplant 2007; 7:1722-1732.
32. Miroux C, Morales O, Carpentier A etal. Inhibitory effects of cyclosporine on human regulatory T cells in vitro. Transplant Proc 2009; 41:3371-3374.
33. Maddur MS, Vani J, Hegde P, Lacroix-Desmazes S, Kaveri SV, Bayry J. Inhibition of differentiation, amplification, and function of human TH17 cells by intravenous immunoglobulin. J Allergy Clin Immunol 2011; 127:823-30 e1-7.
34. Cousens LP, Najafian N, Mingozzi F etal. In vitro and in vivo studies of IgG-derived Treg epitopes (Tregitopes): a promising new tool for tolerance induction and treatment of autoimmunity. J Clin Immunol 2012; 33:43-49.
35. De Groot AS, Moise L, McMurry JA etal. Activation of natural regulatory T cells by IgG Fc-derived peptide 'Tregitopes'. Blood 2008; 112:3303-3311.